HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Trial Profile

HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Anal cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 03 May 2017 Planned initiation date changed from 21 Apr 2017 to 30 Jun 2017.
    • 29 Mar 2017 Planned initiation date changed from 21 Mar 2017 to 21 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top